

Douglas J Jolly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3041391/publications.pdf>

Version: 2024-02-01

29
papers

863
citations

687363

13
h-index

752698

20
g-index

29
all docs

29
docs citations

29
times ranked

922
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. Expert Opinion on Biological Therapy, 2021, 21, 1199-1214.	3.1	11
2	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. Clinical Cancer Research, 2020, 26, 6176-6186.	7.0	13
3	Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.. Journal of Clinical Oncology, 2020, 38, 186-186.	1.6	1
4	PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget, 2019, 10, 2252-2269.	1.8	10
5	Abstract A018: Effects of Toca 511 and Toca FC on tumor microenvironment and peripheral blood populations in patients with advanced malignancies. , 2019, , .		0
6	A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. Molecular Therapy - Oncolytics, 2018, 8, 14-26.	4.4	26
7	Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models. Human Gene Therapy, 2018, 29, 437-451.	2.7	11
8	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-Oncology, 2018, 20, 1383-1392.	1.2	135
9	Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients. Clinical Cancer Research, 2018, 24, 4680-4693.	7.0	20
10	Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Therapy, 2018, 25, 184-195.	4.6	14
11	Abstract B010: Antitumor cellular immune response elicited by Toca 511 and Toca FC therapy in preclinical and clinical studies. , 2018, , .		0
12	Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment. , 2018, , .		0
13	Toca 511 and Toca FC in patients with gastrointestinal tumors in the Toca 6 study.. Journal of Clinical Oncology, 2018, 36, TPS880-TPS880.	1.6	0
14	Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.. Journal of Clinical Oncology, 2018, 36, TPS2613-TPS2613.	1.6	0
15	Abstract CT067: A phase 1b study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer. , 2018, , .		0
16	Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Molecular Therapy - Nucleic Acids, 2017, 6, 221-232.	5.1	12
17	Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro-Oncology, 2017, 19, 930-939.	1.2	65
18	Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro-Oncology, 2017, 19, 918-929.	1.2	41

#	ARTICLE	IF	CITATIONS
19	Prodrug Activator Gene Therapy of Ovarian Cancer using a Retroviral Replicating Vector. <i>Gynecologic Oncology</i> , 2017, 147, 197.	1.4	0
20	Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13504-e13504.	1.6	1
21	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	12.4	158
22	Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types. <i>Human Gene Therapy Methods</i> , 2016, 27, 17-31.	2.1	32
23	Blockade of Type I Interferon (IFN) Production by Retroviral Replicating Vectors and Reduced Tumor Cell Responses to IFN Likely Contribute To Tumor Selectivity. <i>Journal of Virology</i> , 2014, 88, 10066-10077.	3.4	20
24	Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. <i>Neuro-Oncology</i> , 2012, 14, 145-159.	1.2	117
25	Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression. <i>Molecular Therapy</i> , 2012, 20, 1689-1698.	8.2	119
26	Retroviral Replicating Vectors in Cancer. <i>Methods in Enzymology</i> , 2012, 507, 199-228.	1.0	19
27	Evaluation of PCR and ELISA Assays for Screening Clinical Trial Subjects for Replication-Competent Retrovirus. <i>Human Gene Therapy</i> , 1997, 8, 1231-1241.	2.7	37
28	The Manufacture of Genetic Viral Vector Products. , 0, , 229-244.		0
29	Adenoviral Vectors: History and Perspective. , 0, , 39-59.		1